Alumis (ALMS) Stock Overview
A clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ALMS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Alumis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.43 |
| 52 Week High | US$11.57 |
| 52 Week Low | US$2.76 |
| Beta | 0 |
| 1 Month Change | 126.34% |
| 3 Month Change | 162.16% |
| 1 Year Change | 34.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.06% |
Recent News & Updates
Recent updates
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 16
News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts
May 29Alumis: A Best-In-Class TYK2 Inhibitor
Nov 28Alumis: Could This Broken Immunology IPO Become The Next Amgen?
Oct 04Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Sep 16Shareholder Returns
| ALMS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 45.8% | -2.9% | 0.07% |
| 1Y | 34.5% | 16.6% | 11.9% |
Return vs Industry: ALMS exceeded the US Pharmaceuticals industry which returned 16.2% over the past year.
Return vs Market: ALMS exceeded the US Market which returned 12.6% over the past year.
Price Volatility
| ALMS volatility | |
|---|---|
| ALMS Average Weekly Movement | 12.3% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALMS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALMS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 222 | Matt Babler | www.alumis.com |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company’s clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction.
Alumis Inc. Fundamentals Summary
| ALMS fundamental statistics | |
|---|---|
| Market cap | US$1.19b |
| Earnings (TTM) | -US$245.15m |
| Revenue (TTM) | US$22.12m |
Is ALMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMS income statement (TTM) | |
|---|---|
| Revenue | US$22.12m |
| Cost of Revenue | US$0 |
| Gross Profit | US$22.12m |
| Other Expenses | US$267.27m |
| Earnings | -US$245.15m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,108.24% |
| Debt/Equity Ratio | 0% |
How did ALMS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 09:19 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alumis Inc. is covered by 8 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Yatin Suneja | Guggenheim Securities, LLC |